Weight Watchers Announces Third Quarter 2026 Results

Revenue of $153 million; Clinical Subscription Revenue of $38 million, up 48% year-over-year

2.3 million Total End of Period Subscribers; 40% year-over-year Clinical End of Period Subscriber growth to 174 thousand and 16% year-over-year Core+ End of Period Subscriber growth to 546 thousand

Positive Net Income of $15.1 million, representing a 9.9% Net Income Margin; Adjusted EBITDA¹ of $51.7 million, representing a 33.8% Adjusted EBITDA Margin¹

NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced its results for the third quarter of fiscal 2026 ended September 30, 2026² in this Earnings Press Release and a Shareholder Letter issued today and posted on the Company’s Corporate Website.

“Since joining Weight Watchers on October 1, I made it my priority to listen to our members, coaches, clinicians, registered dietitians, and colleagues. Through these conversations, two core truths emerged: weight loss is personal, and the support people need changes along the way,” said Stephen Bye, President and Chief Executive Officer. “Our strength lies in the commitment of our team and our ability to bring together science-backed behavioral programs, clinical care, and the human connection that has defined this brand for more than 60 years. My focus is on strengthening our member experience, improving our products and applications, and building on the work already underway.”

“We remained focused on strengthening our two higher-value product offerings and proactively calibrating our spend across our portfolio,” said Felicia DellaFortuna, Chief Financial Officer. “That approach helped drive sustained progress in these offerings with four quarters of quarter-over-quarter growth in Core+ subscribers, and the largest year-over-year Clinical Subscription Revenue growth percentage in any quarter of 2026 to date. That top-line progress, combined with our continued disciplined investment, directly translated to $51.7 million of Adjusted EBITDA¹, representing a 33.8% Adjusted EBITDA Margin¹.”

Q3 Business Updates

• Q3 Revenue was $152.9 million, down 11% year-over-year. Clinical Subscription Revenue grew 48% year-over-year to $38.0 million and represented 25% of total Revenue, up from 15% in Q3 2025.
• Q3 Total End of Period Subscribers were 2.3 million. Core+ End of Period Subscribers reached 546 thousand, up 16% year-over-year, marking a fourth consecutive quarter of sequential subscriber growth in our higher-value Behavioral membership tier. Clinical End of Period Subscribers were 174 thousand, up 40% year-over-year.
• Monthly Subscription Revenue Per Average Subscriber was $21.17, up 14% year-over-year, reflecting the growing share of our Clinical business and continued growth in Core+ Subscribers.
• Q3 Gross Margin was 71.1% and Adjusted Gross Margin¹ was 74.6%, both the highest of the first three quarters of 2026, compared with 72.1% and 75.1%, respectively, in Q3 2025.
• Net Income for Q3 was $15.1 million, compared to a Net Loss of $57.5 million in Q3 2025. Q3 Adjusted EBITDA¹ increased 21% year-over-year to $51.7 million from $42.8 million in Q3 2025, reflecting continued expense discipline and lower marketing relative to Q3 2025, which included investment to support a product launch.
• Cash and Cash Equivalents were $126.4 million at quarter end, up from $101.5 million at the end of Q2 2026.
  
  

Fiscal 2026 Guidance

The Company narrowed its previously provided full year fiscal 2026 guidance.

• Revenue guidance of $625 million to $630 million, compared to the prior range of $620 million to $635 million.
• Adjusted EBITDA¹ guidance of $110 million to $115 million, compared to the prior range of $105 million to $115 million.
  
  

Third Quarter 2026 Conference Call and Webcast

The Company has scheduled a conference call today at 8:30 a.m. ET to discuss results. The webcast of the conference call will be available on the Company’s corporate website, corporate.ww.com, under Events and Presentations. A replay of the webcast will be available on this site for at least 90 days.

¹Statement regarding Non-GAAP Financial Measures

To supplement the Company’s consolidated results presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company has disclosed non-GAAP financial measures of operating results that exclude or adjust certain items. The Company presents in this release non-GAAP financial measures, including earnings before interest, taxes, depreciation and amortization expenses and share-based compensation expense (“EBITDA”); and for each period presented, EBITDA adjusted, as applicable, for (a) goodwill and other indefinite-lived intangible asset impairments, (b) reorganization items, net related to the Company’s emergence from its Chapter 11 financial reorganization, (c) gain on extinguishment of debt, (d) transaction costs related to strategic alternatives and the Company’s Chapter 11 financial reorganization, (e) net restructuring charges associated with the previously disclosed 2025, 2024, and 2023 restructuring plans, (f) expenses in connection with the management of certain executive matters and (g) other items such as the impact of foreign exchange gains and losses as indicated in the reconciliations below that management believes are not indicative of ongoing operations (“Adjusted EBITDA”). The Company also presents gross profit, gross margin, marketing expenses, selling, general and administrative expenses, and product development expenses on a non-GAAP basis that adjusts for similar items, as further indicated in the reconciliations below.

As exchange rates are an important factor in understanding period-to-period comparisons, the Company believes in certain cases the presentation of results on a constant currency basis in addition to reported results helps improve investors’ ability to understand the Company’s operating results and evaluate the Company’s performance in comparison to prior periods. Constant currency information compares results between periods as if exchange rates had remained constant period-over-period. The Company uses results on a constant currency basis as one measure to evaluate the Company’s performance. In this press release, the Company calculates constant currency by calculating current-year results using prior-year foreign currency exchange rates. The Company generally refers to such amounts calculated on a constant currency basis as excluding or adjusting for the impact of foreign currency or being on a constant currency basis. These results should be considered in addition to, not as a substitute for, results reported in accordance with GAAP and are not meant to be considered in isolation. Results on a constant currency basis, as the Company presents them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP.

Management believes these non-GAAP financial measures provide useful supplemental information to investors regarding the performance of the Company’s business and are useful for period-over-period comparisons of the performance of the Company’s business. While the Company believes that these non-GAAP financial measures are useful in evaluating the Company’s business, this information should be considered as supplemental in nature and is not meant to be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies. See “Reconciliation of Non-GAAP Financial Measures” in this release and reconciliations, if any, included elsewhere in this release for a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures.

A reconciliation of the forward-looking full year Adjusted EBITDA outlook to net income cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of the Company’s control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results.

²Fresh Start Accounting and Predecessor and Successor Periods

In connection with the Company’s emergence from its financial reorganization process on June 24, 2025, the Company applied fresh start accounting which resulted in Successor and Predecessor financial statement presentation. References to “Successor” relate to the Company’s operations for the three and nine months ended September 30, 2026 and the period from June 25, 2025 through September 30, 2025. References to “Predecessor” relate to the Company’s operations for the period December 29, 2024 through June 24, 2025. Accordingly, the consolidated financial statements after June 24, 2025 are not comparable with the consolidated financial statements as of or prior to that date.

Definitions

“Behavioral” business refers to providing subscriptions to the Company’s digital product offerings with the option to upgrade to unlimited access to the Company’s workshops and certain tailored versions of its behavior change program.

“Clinical” business refers to providing subscriptions to the Company’s clinical product offerings provided by Weight Watchers Clinic and third parties combined with the Company’s digital subscription product offerings and unlimited access to the Company’s workshops and certain tailored versions of its behavior change program.

“Revenue” - “Subscription Revenue” consists of the aggregate of: (a) “Behavioral Subscription Revenue”, the fees associated with subscriptions for the Company’s Behavioral offerings; and (b) “Clinical Subscription Revenue”, the fees associated with subscriptions for the Company’s Clinical offerings. In addition, “Other Revenue” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue. “Revenue” consists of the aggregate of Subscription Revenue and Other Revenue.

“Incoming Subscribers” - “Subscribers” refer to Behavioral subscribers and Clinical subscribers who participate in recurring bill programs in Company-owned operations. The “Incoming Subscribers” metric reports Subscribers in Company-owned operations at a given period start. Recruitment and retention are key drivers for this metric. Management utilizes this metric to monitor changes in the subscriber base which directly impacts the Company’s revenue growth and trends.

“End of Period Subscribers” - The “End of Period Subscribers” metric reports Subscribers in Company-owned operations at a given period end. Recruitment and retention are key drivers for this metric. Management utilizes this metric to monitor changes in the subscriber base which directly impacts the Company’s revenue growth and trends.

“Monthly Subscription Revenue Per Average Subscriber” (“ARPU”) - The “Monthly Subscription Revenue Per Average Subscriber” metric reports the monthly fees associated with subscriptions for the Company’s offerings divided by the Average Subscriber for its businesses. Monthly Subscription Revenue for both quarterly and year-to-date periods for each respective business is calculated as Subscription Revenue divided by the number of months in the respective quarterly or year-to-date period. The “Average Subscriber” for quarterly periods for each respective business is the average of its Incoming Subscribers and End of Period Subscribers for the respective quarterly period. The “Average Subscriber” for year-to-date periods for each respective business is the average of its Incoming Subscribers at the beginning of the fiscal year and its End of Period Subscribers for each quarter end within the respective year-to-date period. Management utilizes this metric to consider revenue growth and trends on a per subscriber basis.

About Weight Watchers

Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

This press release includes “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, in particular, any statements about the Company’s plans, strategies, objectives, initiatives, and prospects. The Company generally uses the words “may,” “will,” “could,” “expect,” “anticipate,” “believe,” “estimate,” “plan,” “intend,” “aim” and similar expressions in this press release to identify forward-looking statements. The Company bases these forward-looking statements on its current views with respect to future events and financial performance. Actual results could differ materially from those projected in the forward-looking statements. These forward-looking statements are subject to risks, uncertainties and assumptions, including, among other things: the Company's recent emergence from bankruptcy, which could adversely affect its business and relationships and subjects us to risks and uncertainties; competition from other weight management and health and wellness industry participants or the development of more effective or more favorably perceived weight management methods; the Company's failure to continue to retain and grow its subscriber base; the Company's ability to be a leader in the rapidly evolving and increasingly competitive clinical weight management and weight loss market; the Company's ability to continue to develop new, innovative services and products and enhance its existing services and products or the failure of its services, products or brands to continue to appeal to the market, or its ability to successfully expand into new channels of distribution or respond to consumer trends or sentiment; the Company's ability to successfully implement strategic initiatives; the effectiveness and efficiency of its advertising and marketing programs across multiple platforms, including digital marketing and social media platforms; the impact on the Company's reputation of actions taken by its franchisees, licensees, suppliers, affiliated provider entities, PCs’ healthcare professionals, and other partners; the recognition of asset impairment charges; the loss of key personnel, strategic partners or consultants or failure to effectively manage and motivate the Company's workforce; the Company’s chief executive officer transition; the Company's ability to successfully make acquisitions or enter into collaborations or joint ventures, including its ability to successfully integrate, operate or realize the anticipated benefits of such businesses; uncertainties related to a downturn in general economic conditions or consumer confidence, including as a result of the existing inflationary environment, changes in tariffs and escalating trade tensions, rising interest rates, the potential impact of political and social unrest and increased volatility in the credit and capital markets; the seasonal nature of the Company's business; the Company's failure to maintain effective internal control over financial reporting; the impact of events that impede accessing resources or discourage or impede people from gathering with others; the early termination by us of leases; the inability to renew certain of the Company's licenses, or the inability to do so on terms that are favorable to us; the dependence of the Company's payments system on third-party service providers; the impact of the Company's exposure to variable rate indebtedness; the ability to generate sufficient cash to service the Company's debt and satisfy its other liquidity requirements; uncertainties regarding the satisfactory operation of the Company's technology or systems; the impact of data security breaches and other malicious acts or privacy concerns, including the costs of compliance with evolving privacy laws and regulations; the Company's ability to successfully integrate and use artificial intelligence in its business; the Company's ability to enforce its intellectual property rights both domestically and internationally, as well as the impact of its involvement in any claims related to intellectual property rights; the impact of existing and future laws and regulations; risks related to the Company's exposure to extensive and complex healthcare laws and regulations; the outcomes of litigation or regulatory actions; risks and uncertainties associated with the Company's international operations, including regulatory, economic, political, social, intellectual property, and foreign currency risks, which risks may be exacerbated as a result of war and terrorism; the Company's ability to engage in share repurchases and pay cash dividends in the foreseeable future; risks related to the actions of activist shareholders and anti-takeover provisions in the Company's articles of incorporation and bylaws; risks related to the actions of the Company's shareholders and the exclusive forum provisions in its articles of incorporation; the possibility that the Company could fail to maintain the listing of the Company's common stock on Nasdaq; and other risks and uncertainties, including those included in this press release and those detailed from time to time in the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”) (which are available on the SEC’s EDGAR database at www.sec.gov and via the Company’s website at corporate.ww.com). You should not put undue reliance on any forward-looking statements. You should understand that many important factors, including those discussed herein, could cause the Company’s results to differ materially from those expressed or suggested in any forward-looking statement. Except as required by law, the Company does not undertake any obligation to update or revise these forward-looking statements to reflect new information or events or circumstances that occur after the date of this press release or to reflect the occurrence of unanticipated events or otherwise. Readers are advised to review the Company’s filings with the SEC (which are available on the SEC’s EDGAR database at www.sec.gov and via the Company’s website at corporate.ww.com).

For investor inquiries, please contact:

Anna Kate Heller
WeightWatchers@icrinc.com

For media inquiries, please contact:

Melissa Garbayo
melissa.garbayo@ww.com

WW INTERNATIONAL, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)
UNAUDITED
		Successor
		September 30,				December 31,
			2026				2025
ASSETS
CURRENT ASSETS
	Cash and cash equivalents	$	126,442			$	160,279
	Restricted cash		5,796				6,298
	Receivables (net of allowances: September 30, 2026 - $2,132 and December 31, 2025 - $1,651)		11,977				16,378
	Prepaid income taxes		3,728				8,097
	Prepaid marketing and advertising		2,050				9,275
	Prepaid expenses and other current assets		11,489				13,277
	TOTAL CURRENT ASSETS		161,482				213,604
Property and equipment, net			6,316				8,115
Operating lease assets			1,803				2,933
Goodwill			199,858				200,135
Other intangible assets, net			446,794				490,664
Deferred income taxes			16,209				16,482
Other noncurrent assets			14,871				14,825
	TOTAL ASSETS	$	847,333			$	946,758
LIABILITIES AND EQUITY
CURRENT LIABILITIES
	Portion of operating lease liabilities due within one year	$	918			$	1,260
	Accounts payable		19,644				9,212
	Salaries and wages payable		20,100				34,375
	Accrued marketing and advertising		8,055				22,985
	Accrued interest		892				1,084
	Other accrued liabilities		18,911				23,049
	Income taxes payable		1,644				6,006
	Deferred revenue		21,943				28,565
	TOTAL CURRENT LIABILITIES		92,107				126,536
Long-term debt, net			423,970				465,466
Long-term operating lease liabilities			1,159				1,893
Deferred income taxes			36,253				34,021
Other noncurrent liabilities			576				771
	TOTAL LIABILITIES		554,065				628,687
EQUITY
	Successor common stock, $0 par value; 1,000,000 shares authorized;    9,999 shares issued at September 30, 2026 and 9,992 shares issued at    December 31, 2025		380,136				378,777
	Accumulated deficit		(84,913	)			(62,095	)
	Accumulated other comprehensive (loss) income		(1,955	)			1,389
	TOTAL EQUITY		293,268				318,071
	TOTAL LIABILITIES AND TOTAL EQUITY	$	847,333			$	946,758

WW INTERNATIONAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
UNAUDITED
		Successor
		Three Months Ended				Three Months Ended
		September 30, 2026				September 30, 2025
Subscription revenue, net (1)		$	151,960			$	170,929
Other revenue, net (2)			941				1,162
	Revenue, net		152,901				172,091
Cost of subscription revenue (3)			44,144				47,908
Cost of other revenue			65				72
	Cost of revenue		44,209				47,980
	Gross profit		108,692				124,111
Marketing expenses			33,094				48,404
Product development expenses			5,235				7,550
Selling, general and administrative expenses			33,849				60,122
	Operating income		36,514				8,035
Interest expense			10,861				12,052
Other (income) expense, net			(147	)			342
	Income (loss) before income taxes		25,800				(4,359	)
Provision for income taxes			10,692				53,157
	Net income (loss)	$	15,108			$	(57,516	)
Earnings (net loss) per share
	Basic	$	1.51			$	(5.76	)
	Diluted	$	1.51			$	(5.76	)
Weighted average common shares outstanding
	Basic		9,999				9,987
	Diluted		10,021				9,987
Note: Totals may not sum due to rounding.
(1)  “Subscription revenue, net” consists of the aggregate of: (a) net “Behavioral Subscription Revenue”, the fees associated with subscriptions for the Company’s Behavioral offerings; and (b) net “Clinical Subscription Revenue”, the fees associated with subscriptions for the Company’s Clinical offerings.
(2)  “Other revenue, net” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue.
(3)  “Cost of subscription revenue” consists of cost of revenue and operating expenses for the Company's Behavioral and Clinical services.

WW INTERNATIONAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
UNAUDITED
		Successor									Predecessor
						Period from					Period from
		Nine Months Ended September 30, 2026				June 25, 2025					December 29, 2024
						through September 30, 2025					through June 24, 2025
Subscription revenue, net(1)		$	480,710			$	183,007				$	360,953
Other revenue, net(2)			2,777				1,251					2,615
	Revenue, net		483,487				184,258					363,568
Cost of subscription revenue(3)			141,603				51,166					100,026
Cost of other revenue			377				72					158
	Cost of revenue		141,980				51,238					100,184
	Gross profit		341,507				133,020					263,384
Marketing expenses			173,903				51,188					110,871
Product development expenses			19,768				8,236					25,281
Selling, general and administrative expenses			132,286				62,975					78,480
Franchise rights acquired impairments			—				—					27,549
	Operating income		15,550				10,621					21,203
Reorganization items, net			—				—					(1,143,918	)
Interest expense			33,925				12,975					38,664
Gain on extinguishment of debt			(4,612	)			—					—
Other (income) expense, net			(1,305	)			1,274					6,685
	(Loss) income before income taxes		(12,458	)			(3,628	)				1,119,772
Provision for income taxes			10,360				52,634					1,669
	Net (loss) income	$	(22,818	)		$	(56,262	)			$	1,118,103
(Net loss) earnings per share
	Basic	$	(2.28	)		$	(5.63	)			$	13.93
	Diluted	$	(2.28	)		$	(5.63	)			$	13.80
Weighted average common shares outstanding
	Basic		9,998				9,987					80,271
	Diluted		9,998				9,987					80,998
Note: Totals may not sum due to rounding.
(1)“Subscription revenue, net” consists of the aggregate of: (a) net “Behavioral Subscription Revenue”, the fees associated with subscriptions for the Company’s Behavioral offerings; and (b) net “Clinical Subscription Revenue”, the fees associated with subscriptions for the Company’s Clinical offerings.
(2)“Other revenue, net” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue.
(3)“Cost of subscription revenue” consists of cost of revenue and operating expenses for the Company's Behavioral and Clinical services.

WW INTERNATIONAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
UNAUDITED
		Successor									Predecessor
						Period from					Period from
		Nine Months Ended September 30, 2026				June 25, 2025					December 29, 2024
						through September 30, 2025					through June 24, 2025
Operating activities:
	Net (loss) income	$	(22,818	)		$	(56,262	)			$	1,118,103
	Adjustments to reconcile net (loss) income to cash provided by (used for) operating activities:
	Depreciation and amortization		64,851				27,174					14,201
	Amortization of deferred financing costs and debt (premium) discount, net		(76	)			(26	)				1,766
	Impairment of franchise rights acquired		—				—					27,549
	Impairment of long-lived assets		3				—					97
	Share-based compensation expense		1,324				—					4,032
	Deferred tax provision		1,970				1,064					26,232
	Allowance for doubtful accounts		48				(513	)				(1,131	)
	Foreign currency exchange rate (gain) loss		(1,206	)			1,298					6,717
	Non-cash reorganization items, net		—				—					(1,176,532	)
	Gain on extinguishment of debt		(4,612	)			—					—
	Changes in cash due to:
	Receivables		4,169				(2,245	)				4,280
	Prepaid expenses		13,537				39,934					(31,281	)
	Accounts payable		10,466				1,454					(8,237	)
	Accrued liabilities		(33,680	)			(14,623	)				15,084
	Deferred revenue		(6,397	)			(2,220	)				(2,914	)
	Other long term assets and liabilities, net		(191	)			(11	)				(2,234	)
	Income taxes		(4,349	)			13,394					(30,155	)
	Cash provided by (used for) operating activities		23,039				8,418					(34,423	)
Investing activities:
	Capital expenditures		—				(6	)				(87	)
	Capitalized software and website development expenditures		(18,899	)			(3,678	)				(6,253	)
	Cash paid for acquisitions, net of cash acquired		—				(1,020	)				—
	Other items, net		—				(3	)				(1	)
	Cash used for investing activities		(18,899	)			(4,707	)				(6,341	)
Financing activities:
	Borrowings on revolving credit facility		—				—					171,341
	Financing costs		—				—					(1,298	)
	Payments on long-term debt		(36,808	)			—					—
	Taxes paid related to net share settlement of equity awards		—				—					(145	)
	Cash paid for acquisitions		—				—					(16,000	)
	Cash (used for) provided by financing activities		(36,808	)			—					153,898
Effect of exchange rate changes on cash and cash equivalents and restricted cash			(1,671	)			235					3,966
Net (decrease) increase in cash and cash equivalents and restricted cash			(34,339	)			3,946					117,100
Cash and cash equivalents and restricted cash, beginning of period			166,577				173,620					56,520
Cash and cash equivalents and restricted cash, end of period		$	132,238			$	177,566				$	173,620

WW INTERNATIONAL, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
(IN THOUSANDS, EXCEPT PERCENTAGES)
UNAUDITED
											Variance
		Successor												2026
		Three Months Ended						Three Months Ended			2026			Constant Currency
		September 30, 2026						September 30, 2025			vs			vs
		GAAP			Constant Currency			GAAP			2025			2025
Selected Financial Data
Revenue(1)		$	152,901		$	153,270		$	172,091		(11.2	%)		(10.9	%)
Behavioral Subscription Revenue(2)		$	113,923		$	114,286		$	145,152		(21.5	%)		(21.3	%)
Clinical Subscription Revenue(3)		$	38,037		$	38,037		$	25,777		47.6	%		47.6	%
Subscription Revenue(4)		$	151,960		$	152,323		$	170,929		(11.1	%)		(10.9	%)
Other Revenue(5)		$	941		$	947		$	1,162		(19.0	%)		(18.5	%)
Note: Totals may not sum due to rounding.
(1) “Revenue” consists of the aggregate of Subscription Revenue and Other Revenue.
(2) “Behavioral Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Behavioral offerings.
(3) “Clinical Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Clinical offerings.
(4) “Subscription Revenue” is the sum of Behavioral Subscription Revenue and Clinical Subscription Revenue.
(5) “Other Revenue” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue.

WW INTERNATIONAL, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
(IN THOUSANDS, EXCEPT PERCENTAGES)
UNAUDITED
											Variance
														2026
		Successor									2026			Constant Currency
		Nine Months Ended						Nine Months Ended			vs			vs
		September 30, 2026						September 30, 2025			2025			2025
		GAAP			Constant Currency			Combined(1)			Combined			Combined
Selected Financial Data
Revenue(2)		$	483,487		$	478,801		$	547,826		(11.7	%)		(12.6	%)
Behavioral Subscription Revenue(3)		$	363,933		$	359,291		$	458,133		(20.6	%)		(21.6	%)
Clinical Subscription Revenue(4)		$	116,777		$	116,778		$	85,827		36.1	%		36.1	%
Subscription Revenue(5)		$	480,710		$	476,070		$	543,960		(11.6	%)		(12.5	%)
Other Revenue(6)		$	2,777		$	2,732		$	3,866		(28.2	%)		(29.3	%)
Note: Totals may not sum due to rounding.
(1) These amounts combine the revenue of the Successor and Predecessor periods for comparability purposes. Although the Successor and Predecessor have a different accounting basis due to the application of fresh start accounting, none of the fresh start accounting adjustments impact revenue. Therefore, the combined revenue amounts presented are consistent with a pro forma presentation under Article 11 of Regulation S-X as if fresh start accounting was applied at the beginning of the first period presented.
(2) “Revenue” consists of the aggregate of Subscription Revenue and Other Revenue.
(3) “Behavioral Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Behavioral offerings.
(4) “Clinical Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Clinical offerings.
(5) “Subscription Revenue” is the sum of Behavioral Subscription Revenue and Clinical Subscription Revenue.
(6) “Other Revenue” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue.

WW INTERNATIONAL, INC. AND SUBSIDIARIES
OPERATIONAL STATISTICS
(IN THOUSANDS, EXCEPT PERCENTAGES AND MONTHLY SUBSCRIPTION REVENUE PER AVERAGE SUBSCRIBER)
UNAUDITED
		Successor
		Three Months Ended						Three Months Ended
		September 30, 2026						September 30, 2025			Variance			Variance
					(Constant Currency)									(Constant Currency)
Incoming Subscribers(1)
Incoming Behavioral Subscribers			2,291		N/A				3,040		(24.6	%)		N/A
Incoming Clinical Subscribers			197		N/A				127		55.7	%		N/A
Incoming Subscribers			2,489		N/A				3,167		(21.4	%)		N/A
End of Period Subscribers(2)
End of Period Behavioral Subscribers			2,122		N/A				2,862		(25.9	%)		N/A
End of Period Clinical Subscribers			174		N/A				124		40.4	%		N/A
End of Period Subscribers			2,296		N/A				2,986		(23.1	%)		N/A
Monthly Subscription Revenue Per Average Subscriber(3)
Monthly Behavioral Subscription Revenue Per Average Subscriber		$	17.21		$	17.26		$	16.39		5.0	%		5.3	%
Monthly Clinical Subscription Revenue Per Average Subscriber		$	68.25		$	68.25		$	68.52		(0.4	%)		(0.4	%)
Monthly Subscription Revenue Per Average Subscriber		$	21.17		$	21.22		$	18.52		14.3	%		14.6	%
Note: Totals may not sum due to rounding.
(1) The “Incoming Subscribers” metric reports WW subscribers in Company-owned operations at a given period start.
(2) The “End of Period Subscribers” metric reports WW subscribers in Company-owned operations at a given period end.
(3) The “Monthly Subscription Revenue Per Average Subscriber” metric reports the monthly fees associated with subscriptions for the Company's offerings divided by the Average Subscriber for its businesses. Monthly Subscription Revenue for quarterly periods for each respective business is calculated as Subscription Revenue divided by the number of months in the respective quarterly period. The “Average Subscriber” for quarterly periods for each respective business is the average of its Incoming Subscribers and End of Period Subscribers for the respective quarterly period.

WW INTERNATIONAL, INC. AND SUBSIDIARIES
OPERATIONAL STATISTICS
(IN THOUSANDS, EXCEPT PERCENTAGES AND MONTHLY SUBSCRIPTION REVENUE PER AVERAGE SUBSCRIBER)
UNAUDITED
		Successor						Combined
		Nine Months Ended						Nine Months Ended
		September 30, 2026						September 30, 2025			Variance			Variance
					(Constant Currency)									(Constant Currency)
Incoming Subscribers(1)
Incoming Behavioral Subscribers			2,631		N/A				3,244		(18.9	%)		N/A
Incoming Clinical Subscribers			130		N/A				92		41.9	%		N/A
Incoming Subscribers			2,761		N/A				3,336		(17.2	%)		N/A
End of Period Subscribers(2)
End of Period Behavioral Subscribers			2,122		N/A				2,862		(25.9	%)		N/A
End of Period Clinical Subscribers			174		N/A				124		40.4	%		N/A
End of Period Subscribers			2,296		N/A				2,986		(23.1	%)		N/A
Monthly Subscription Revenue Per Average Subscriber(3)
Monthly Behavioral Subscription Revenue Per Average Subscriber		$	17.00		$	16.78		$	16.43		3.5	%		2.2	%
Monthly Clinical Subscription Revenue Per Average Subscriber		$	74.33		$	74.33		$	78.30		(5.1	%)		(5.1	%)
Monthly Subscription Revenue Per Average Subscriber		$	20.92		$	20.72		$	18.71		11.8	%		10.7	%
Note: Totals may not sum due to rounding.
(1)The “Incoming Subscribers” metric reports WW subscribers in Company-owned operations at a given period start.
(2)The “End of Period Subscribers” metric reports WW subscribers in Company-owned operations at a given period end.
(3)The “Monthly Subscription Revenue Per Average Subscriber” metric reports the monthly fees associated with subscriptions for the Company's offerings divided by the Average Subscriber for its businesses. Monthly Subscription Revenue for year-to-date periods for each respective business is calculated as Subscription Revenue divided by the number of months in the respective year-to-date period. The “Average Subscriber” for year-to-date periods for each respective business is the average of its Incoming Subscribers at the beginning of the fiscal year and its End of Period Subscribers for each quarter end within the respective year-to-date period.

WW INTERNATIONAL, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
(IN THOUSANDS, EXCEPT PERCENTAGES)
UNAUDITED
		Successor
		Three Months Ended																Three Months Ended
		September 30, 2026																September 30, 2025
														Selling,																Selling,
										Product				General, and												Product				General, and
		Gross				Marketing				Development				Administrative				Gross				Marketing				Development				Administrative
		Profit				Expenses				Expenses				Expenses				Profit				Expenses				Expenses				Expenses
GAAP		$	108,692			$	33,094			$	5,235			$	33,849			$	124,111			$	48,404			$	7,550			$	60,122
% of Revenue			71.1%				21.6%				3.4%				22.1%				72.1%				28.1%				4.4%				34.9%
Adjustments:
Transaction Costs(1)		$	—			$	—			$	—			$	—			$	—			$	—			$	—			$	(9,126	)
Depreciation and Amortization Expenses			5,353				—				—				(7,696	)			5,135				—				(58	)			(20,301	)
Restructuring Charges(2)			—				—				—				—				23				—				—				(99	)
Share-based Compensation Expense			0				(20	)			(99	)			(586	)			—				—				—				—
Executive Related Costs(3)			—				(856	)			—				(535	)			—				—				—				—
Total Adjustments		$	5,354			$	(875	)		$	(99	)		$	(8,816	)		$	5,158			$	—			$	(58	)		$	(29,525	)
Adjusted		$	114,046			$	32,219			$	5,136			$	25,033			$	129,269			$	48,404			$	7,492			$	30,597
% of Revenue			74.6%				21.1%				3.4%				16.4%				75.1%				28.1%				4.4%				17.8%
Currency Adjustment			334				40				2				19			N/A				N/A				N/A				N/A
Constant Currency		$	109,026			$	33,134			$	5,237			$	33,868			N/A				N/A				N/A				N/A
% of Revenue			71.1%				21.6%				3.4%				22.1%			N/A				N/A				N/A				N/A
Adjusted Constant Currency		$	114,380			$	32,259			$	5,138			$	25,052			N/A				N/A				N/A				N/A
% of Revenue			74.6%				21.0%				3.4%				16.3%			N/A				N/A				N/A				N/A
Note: Totals may not sum due to rounding.
(1)Certain non-recurring transaction costs related to strategic alternatives and the Company's Chapter 11 financial reorganization.
(2)Restructuring charges, from previously disclosed restructuring plans, consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments.
(3)Expenses in connection with the management of certain executive matters.

WW INTERNATIONAL, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
(IN THOUSANDS, EXCEPT PERCENTAGES)
UNAUDITED
		Successor																																	Predecessor
																		Period from																	Period from
		Nine Months Ended																June 25, 2025																	December 29, 2024
		September 30, 2026																through September 30, 2025																	through June 24, 2025
														Selling,																Selling,																	Selling,
										Product				General, and												Product				General, and													Product				General, and
		Gross				Marketing				Development				Administrative				Gross				Marketing				Development				Administrative					Gross				Marketing				Development				Administrative
		Profit				Expenses				Expenses				Expenses				Profit				Expenses				Expenses				Expenses					Profit				Expenses				Expenses				Expenses
GAAP		$	341,507			$	173,903			$	19,768			$	132,286			$	133,020			$	51,188			$	8,236			$	62,975				$	263,384			$	110,871			$	25,281			$	78,480
% of Revenue			70.6%				36.0%				4.1%				27.4%				72.2%				27.8%				4.5%				34.2%					72.4%				30.5%				7.0%				21.6%
Adjustments:
Transaction Costs(1)		$	—			$	—			$	—			$	—			$	—			$	—			$	—			$	(9,308	)			$	—			$	—			$	—			$	(20,873	)
Depreciation and Amortization Expenses			15,865				—				—				(48,986	)			5,465				—				(62	)			(21,647	)				8,650				—				(115	)			(5,440	)
Restructuring Charges(2)			(65	)			—				—				(377	)			23				—				—				(99	)				(2,455	)			—				—				(2,333	)
Share-based Compensation Expense			1				(321	)			(317	)			(1,484	)			—				—				—				—					—				—				—				(4,032	)
Executive Related Costs(3)			—				(856	)			—				(5,897	)			—				—				—				—					—				—				—				—
Total Adjustments		$	15,801			$	(1,176	)		$	(317	)		$	(56,745	)		$	5,488			$	—			$	(62	)		$	(31,054	)			$	6,195			$	—			$	(115	)		$	(32,677	)
Adjusted		$	357,308			$	172,727			$	19,451			$	75,541			$	138,508			$	51,188			$	8,174			$	31,921				$	269,579			$	110,871			$	25,166			$	45,803
% of Revenue			73.9%				35.7%				4.0%				15.6%				75.2%				27.8%				4.4%				17.3%					74.1%				30.5%				6.9%				12.6%
Currency Adjustment			(4,054	)			(988	)			(8	)			(294	)		N/A				N/A				N/A				N/A					N/A				N/A				N/A				N/A
Constant Currency		$	337,453			$	172,915			$	19,760			$	131,992			N/A				N/A				N/A				N/A					N/A				N/A				N/A				N/A
% of Revenue			70.5%				36.1%				4.1%				27.6%			N/A				N/A				N/A				N/A					N/A				N/A				N/A				N/A
Adjusted Constant Currency		$	353,254			$	171,739			$	19,443			$	75,248			N/A				N/A				N/A				N/A					N/A				N/A				N/A				N/A
% of Revenue			73.8%				35.9%				4.1%				15.7%			N/A				N/A				N/A				N/A					N/A				N/A				N/A				N/A
Note: Totals may not sum due to rounding.
(1) Certain non-recurring transaction costs related to strategic alternatives and the Company's Chapter 11 financial reorganization.
(2) Restructuring charges consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments. Restructuring charges include the previously disclosed 2025 restructuring plan, the previously disclosed 2024 restructuring plan and the previously disclosed 2023 restructuring plan.
(3) Expenses in connection with the management of certain executive matters.

WW INTERNATIONAL, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
(IN THOUSANDS, EXCEPT PERCENTAGES)
UNAUDITED
		Successor																	Predecessor
														Period from					Period from
		Three Months Ended September 30, 2026				Nine Months Ended September 30, 2026				Three Months Ended September 30, 2025				June 25, 2025					December 29, 2024
														through September 30, 2025					through June 24, 2025
Net Income (Loss)		$	15,108			$	(22,818	)		$	(57,516	)		$	(56,262	)			$	1,118,103
Net Income (Loss) Margin			9.9%				(4.7	%)			(33.4	%)			(30.5	%)				307.5%
Interest			10,861				33,925				12,052				12,975					38,664
Taxes			10,692				10,360				53,157				52,634					1,669
Depreciation and Amortization Expenses			13,050				64,851				25,493				27,174					14,201
Share-based Compensation Expense			705				2,123				—				—					4,032
	EBITDA	$	50,416			$	88,441			$	33,186			$	36,521				$	1,176,669
	EBITDA Margin		33.0%				18.3%				19.3%				19.8%					323.6%
Franchise Rights Acquired Impairments(1)			—				—				—				—					27,549
Reorganization Items, net(2)			—				—				—				—					(1,143,918	)
Gain on Extinguishment of Debt(3)			—				(4,612	)			—				—					—
Transaction Costs(4)			—				—				9,126				9,308					20,873
Restructuring Charges(5)			—				313				122				122					(122	)
Executive Related Costs(6)			1,391				6,752				—				—					—
Other(7)			(147	)			(1,305	)			342				1,274					6,685
	Adjusted EBITDA	$	51,660			$	89,589			$	42,776			$	47,225				$	87,736
	Adjusted EBITDA Margin		33.8%				18.5%				24.9%				25.6%					24.1%
Note: Totals may not sum due to rounding.
(1) The Company's franchise rights acquired impairment charge related to its United States unit of account.
(2) The net reorganization gain related to the Company's emergence from its Chapter 11 financial reorganization and primarily consisted of the gain on settlement of liabilities subject to compromise and the impacts of fresh start valuation adjustments.
(3) Gain on extinguishment of debt consists of the Company's voluntary prepayment in May 2026 of a portion of its New Term Loan Facility at 68.5% of par.
(4) Certain non-recurring transaction costs related to strategic alternatives and the Company's Chapter 11 financial reorganization.
(5) Restructuring charges consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments. Restructuring charges include the previously disclosed 2025 restructuring plan, the previously disclosed 2024 restructuring plan and the previously disclosed 2023 restructuring plan.
(6) Expenses in connection with the management of certain executive matters.
(7) Primarily consists of the impact of foreign currency on intercompany transactions.